Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Oral anticoagulation, primarily Vitamin K antagonists (VKAs) like warfarin, is crucial for preventing stroke in atrial fibrillation (AF).
• VKAs have limitations including unpredictable effects, narrow therapeutic index, and need for routine monitoring, posing challenges for patients and healthcare systems.
• Development of novel oral anticoagulants (NOACs) targeting specific factors like thrombin or Factor Xa aims to overcome VKA limitations.

Purpose of the Study:

• To evaluate the efficacy and safety of dabigatran etexilate compared to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF).

Main Methods:

• The Randomized Evaluation of Long-Term Anticoagulation (RE-LY) trial enrolled 18,113 patients with NVAF and at least one stroke risk factor.
• Patients received either warfarin, dabigatran etexilate 150 mg twice daily, or dabigatran etexilate 110 mg twice daily.
• Outcomes assessed included stroke, systemic embolism, major bleeding, and intracranial bleeding.

Main Results:

• Dabigatran etexilate 150 mg twice daily reduced stroke or systemic embolism by one-third versus warfarin, with similar major bleeding rates.
• Dabigatran etexilate 110 mg twice daily showed similar rates of stroke or systemic embolism but reduced major bleeding by one-fifth compared to warfarin.
• Both dabigatran doses significantly reduced intracranial bleeding by approximately two-thirds compared to warfarin.

Conclusions:

• Dabigatran etexilate is an effective and safe alternative to warfarin for stroke prevention in NVAF patients.
• The 150 mg twice daily dose offers superior stroke risk reduction, while the 110 mg twice daily dose provides a better bleeding profile.
• Regulatory approvals by the US FDA and Health Canada support dabigatran etexilate's use in NVAF.